175 related articles for article (PubMed ID: 27686966)
1. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.
Jaroch K; Karolak M; Górski P; Jaroch A; Krajewski A; Ilnicka A; Sloderbach A; Stefański T; Sobiak S
Pharmacol Rep; 2016 Dec; 68(6):1266-1275. PubMed ID: 27686966
[TBL] [Abstract][Full Text] [Related]
2. Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications.
Karatoprak GŞ; Küpeli Akkol E; Genç Y; Bardakci H; Yücel Ç; Sobarzo-Sánchez E
Molecules; 2020 May; 25(11):. PubMed ID: 32486408
[TBL] [Abstract][Full Text] [Related]
3. Combretastatin A4 phosphate: background and current clinical status.
Young SL; Chaplin DJ
Expert Opin Investig Drugs; 2004 Sep; 13(9):1171-82. PubMed ID: 15330748
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy.
Faustino C; Francisco AP; Isca VMS; Duarte N
Curr Pharm Des; 2018; 24(36):4270-4311. PubMed ID: 30636588
[TBL] [Abstract][Full Text] [Related]
5. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.
Marrelli M; Conforti F; Statti GA; Cachet X; Michel S; Tillequin F; Menichini F
Curr Med Chem; 2011; 18(20):3035-81. PubMed ID: 21651481
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumour vasculature: the development of combretastatin A4.
Griggs J; Metcalfe JC; Hesketh R
Lancet Oncol; 2001 Feb; 2(2):82-7. PubMed ID: 11905799
[TBL] [Abstract][Full Text] [Related]
7. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Siemann DW; Chaplin DJ; Walicke PA
Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
[TBL] [Abstract][Full Text] [Related]
8. Tubulin-interactive stilbene derivatives as anticancer agents.
Mikstacka R; Stefański T; Różański J
Cell Mol Biol Lett; 2013 Sep; 18(3):368-97. PubMed ID: 23818224
[TBL] [Abstract][Full Text] [Related]
9. Combretastatins: more than just vascular targeting agents?
Greene LM; Meegan MJ; Zisterer DM
J Pharmacol Exp Ther; 2015 Nov; 355(2):212-27. PubMed ID: 26354991
[TBL] [Abstract][Full Text] [Related]
10. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum.
Pettit GR; Singh SB; Niven ML; Hamel E; Schmidt JM
J Nat Prod; 1987; 50(1):119-31. PubMed ID: 3598594
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
12. Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4.
Brown AW; Fisher M; Tozer GM; Kanthou C; Harrity JP
J Med Chem; 2016 Oct; 59(20):9473-9488. PubMed ID: 27690431
[TBL] [Abstract][Full Text] [Related]
13. Combretastatins: from natural products to drug discovery.
Cirla A; Mann J
Nat Prod Rep; 2003 Dec; 20(6):558-64. PubMed ID: 14700199
[TBL] [Abstract][Full Text] [Related]
14. Discovery, synthesis, activities, structure-activity relationships, and clinical development of combretastatins and analogs as anticancer drugs. A comprehensive review.
Singh SB
Nat Prod Rep; 2024 Feb; 41(2):298-322. PubMed ID: 38009216
[TBL] [Abstract][Full Text] [Related]
15. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
16. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.
Nabha SM; Mohammad RM; Dandashi MH; Coupaye-Gerard B; Aboukameel A; Pettit GR; Al-Katib AM
Clin Cancer Res; 2002 Aug; 8(8):2735-41. PubMed ID: 12171907
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
Cushman M; Nagarathnam D; Gopal D; Chakraborti AK; Lin CM; Hamel E
J Med Chem; 1991 Aug; 34(8):2579-88. PubMed ID: 1875350
[TBL] [Abstract][Full Text] [Related]
18. Combretastatin A-4 analogues as antimitotic antitumor agents.
Nam NH
Curr Med Chem; 2003 Sep; 10(17):1697-722. PubMed ID: 12871118
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Sydnone-Based Analogues of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy.
Brown AW; Holmes T; Fisher M; Tozer GM; Harrity JPA; Kanthou C
ChemMedChem; 2018 Dec; 13(24):2618-2626. PubMed ID: 30281922
[TBL] [Abstract][Full Text] [Related]
20. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
